MRM-based validation assay for serum proteomic alterations in meningioma patients

Meningiomas are tumors that arise from the outer layering of the brain namely the dura, arachnoid and pia mater. These tumors account for nearly 30% of all primary brain tumors and are majorly treated via surgical resection. WHO classifies meningiomas into three types namely the benign (MGI),atypical (MGII) and anaplastic (MGIII). Recently there are reports of aggravated recurrence rates and diagnostic ambiguity within the grades and certain molecular signatures have been ascribed to such manifestation.
However apart from the conventional modalities of treatment there are no molecular markers that can be used for diagnosis and prognosis of these tumors. In this study we attempt to validate differentially expressed proteins in meningioma patients and assess its utility in context to meningioma pathobiology.